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ABSTRACT
Endoscopy is a central tool for the evaluation and management of inflam-
matory bowel disease (IBD). In the last few decades, gastrointestinal (GI)
endoscopy has undergone significant technological developments includ-
ing availability of pediatric-size equipment, enabling comprehensive
investigation of the GI tract in children. Simultaneously, professional
organization of GI experts have developed guidelines and training pro-
grams in pediatric GI endoscopy. This prompted the Porto Group on
Pediatric IBD of the European Society for Pediatric Gastroenterology,
Hepatology and Nutrition to develop updated guidelines on the role of GI
endoscopy in pediatric IBD, specifically taking into considerations of
recent advances in the diagnosis, disease stratification, and novel thera-
peutic targets in these patients.
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(JPGN 2018;67: 414–430)
INTRODUCTION
E ndoscopy is a central tool for the evaluation and managementof inflammatory bowel disease (IBD). In the last few decades,
gastrointestinal (GI) endoscopy has undergone significant advances
and adaptation for application in pediatric patients, facilitating
comprehensive investigation of the GI tract in infants and children.
Simultaneously, scientific organizations have developed guidelines
and training programs in pediatric GI endoscopy (1).
There are currently no specific pediatric IBD (PIBD) endos-
copy guidelines, although recently published European Society for
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Pediatric Endoscopy Guidelines refer to the subject matter (1). This
prompted the Porto Group on Pediatric IBD of the European Society
for Pediatric Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) to develop a position paper on the role of GI endoscopy in
PIBD, specifically taking into consideration recent advances in
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PIBD pertaining to diagnosis, disease stratifications and emerging
therapeutic targets.
METHODS
Scope and Purpose
The Pediatric IBD Porto Group of ESPGHAN developed
guidelines on diagnostic approach to PIBD in 2014 (2). As endos-
copy was only considered in the context of the diagnostic workup,
the Porto Group set out to develop PIBD-specific endoscopy
position paper following review the current literature.
Literature Review
An initial systematic literature search was conducted using
PubMed,Medline, Embase, Cochrane Library, and Scopus databases
until November 2015 using the following MESH terms ((‘‘Adoles-
cent’’ [Mesh] OR ‘‘Child’’ [Mesh] OR ‘‘Infant’’ [Mesh] OR ‘‘Min-
ors’’ [Mesh] or ‘‘Pediatrics’’ [Mesh]) AND (‘‘Endoscopy’’ [Mesh]
OR ‘‘endoscope’’ [Mesh] OR ‘‘videoendoscopy’’ [Mesh] OR
‘‘Endoscopy, Digestive System’’ [Mesh]) AND (‘‘Inflammatory
Bowel Diseases’’[Mesh] OR ‘‘Enteritis’’[Mesh] OR ‘‘Colitis’’[-
Mesh] OR ‘‘Ileitis’’[Mesh] OR ‘‘Crohn disease’’[Mesh] OR ‘‘Proc-
titis’’[Mesh]). Studies were restricted to humans and non-English
publications were excluded.
Review, Grading of Evidence, and Consensus
Process
Twomembers of the Porto Group (L.d.R. and S.C.) identified
the following main topics: diagnosis; endoscopic monitoring; small
bowel (SB) endoscopy; therapeutic endoscopy; and surveillance.
An open call for participants for the project occurred among
Porto Group members, Porto interest group and ESPGHAN mem-
bers. Contributors were selected by a steering committee (S.C.,
L.d.R., D.T., M.T., S.O.) on the basis of a statement, their personal
curriculum vitae and publications. The selected consensus group
included pediatric gastroenterologists and endoscopists expert in
the field of IBD.
Each topic had a working group (WG), a Chair and different
participants. Each WG performed an extensive literature search on
the assigned topic by using appropriate keywords through Medline/
PubMed/ISI/Scopus and the Cochrane database in November 2015.
All the available studies until November 2015 were included. A
second search and update of the evidence was performed after the
authors’ voting process in September 2017. Finally, new relevant
references were also included at the end of the peer-review revision
process in December 2017.
The working parties then met twice in 2015 (Amsterdam and
Barcelona) and once in 2016 (in Porto) to revise and develop
agreement with the statements. Each statement was revised until
consensus was reached. The panel then voted on all recommenda-
tions and practice points, while adding specific comments using a
web-based voting platform. The document was revised again based
on comments received. A second round of electronic voting and
revisions was done, including the entire members of the Pediatric
IBD group of ESPGHAN.
The Consensus Statement was reached at >80%
participant agreement.
For each statement, the level of evidence (EL) and the
grading of recommendations (RG) were given according to the
Oxford Centre for Evidence Based Medicine 2011 (Table 1, https://
www.cebm.net/2011/06/explanation-2011-ocebm-levels-evidence).
MANUSCRIPT
Each WG provided a summary of written background evi-
dence for statements to draft the initial manuscript by S.O. and S.C.
The manuscript was circulated to the consensus group for revisions
and to the Porto IBD Group of ESPGHAN before submission for
publication. The final text was edited for consistency of style by S.C.,
D.T., and S.O., for approval by the journal and ESPGHAN council.
Recommendations
Table 2 provides a synopsis of the recommendations.
The Position Paper includes not only recommendations but
also ‘‘practice points’’ that reflect common practice wherein evi-
dence is lacking. Weaker recommendations are indicated by phrases
such as ‘‘we suggest,’’ whereas stronger recommendations are
typically stated as ‘‘we recommend.’’ Recommendations are
intended to be read in context with the qualifying comments in
the accompanying text.
DIAGNOSIS
Recommendations:
1. In non-emergency situations, the diagnostic evaluation for
suspected IBD in children should include a combination of
esophagogastroduodenoscopy (EGD) and ileocolonoscopy (IC)
[EL4, RGC]. (97% agreement)
2. During IC and EGD, multiple biopsies (2) should be obtained
from each segment even in the absence of macroscopic lesions
[EL4, RGC]. (90% agreement)
Practice points:
(1) Pediatric Endoscopy should be performed by a pediatric
gastroenterologist, or in some cases, by a gastroenterologist
with specific pediatric training and/or supported by a pediatric
team in a pediatric-friendly setting, as described in the recent
ESPGHAN/European Society for Gastrointestinal Endoscopy
(ESGE) guidelines (1).
(2) According to the revised Porto Criteria, endoscopy is usually
recommended in the presence of alarming symptoms (ie,
bloody diarrhea, weight loss, abdominal pain) and/or positive
serum inflammatory markers (C-CRP) an/or ESR), and/or high
levels of fecal calprotectin.
(3) It is recommended to collect 2 biopsies samples from
duodenum, stomach and esophagus during EGD, and from
terminal ileum, cecum, transverse colon, sigmoid colon, and
rectum during IC.
(4) In severe acute colitis, a limited sigmoidoscopy may be safer
than doing a complete colonoscopy. A follow-up colonoscopy
should be performed after the resolution of an acute attack;
however, in experienced hands, total colonoscopy can often
safely be completed even during acute attacks.
Endoscopy remains the fundamental diagnostic tool for IBD
in both adults and children. IC should include complete colonos-
copy with ileal intubation (1,2). Indeed, colonic involvement is
more frequent in pediatric Crohn disease (CD) than in adult(s), and
the diagnosis cannot be based exclusively on sigmoidoscopy or
partial colonoscopy, as ileal intubation can suggest or confirm CD
diagnosis (3). Unfortunately, failure to visualize the terminal ileum
is reported in around 20% to 25% of pediatric cases (4). For this
reason, it is crucial that endoscopy for pediatric IBD should be
performed by pediatric or adult gastroenterologists with adequate
training (1). Endoscopy is usually recommended when alarm
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symptoms or signs, positive blood markers, and/or high levels of
fecal calprotectin are present (2). In a recent meta-analysis, fecal
calprotectin added the most diagnostic value to symptoms com-
pared with commonly used blood markers. Fecal calprotectin
should precede endoscopy in the diagnostic evaluation of referred
pediatric patients with symptoms suggestive of IBD, since its higher
fecal calprotectin levels considerably increases the likelihood to
find inflammatory lesions (5). Endoscopy of the ileo-colon should
be deferred in cases of toxic megacolon, while in cases of acute
severe colitis, sigmoidoscopy or partial/full IC may be considered in
expert hands. The Porto Criteria and ESPGHAN Paediatric Endos-
copy Guidelines, based on strong evidence-based data, that EGD
should be performed in all children at the initial evaluation of
disease irrespective of the presence or absence of upper gastroin-
testinal symptoms (2). Absence of specific upper gastrointestinal
symptoms does not preclude presence of upper gastrointestinal
inflammation. In a retrospective study of 172 children with sus-
pected IBD, the diagnosis was changed to CD based on biopsies
obtained at EGD (6). Data from the PIBD registry found that EGD
helped to establish the final diagnosis in 10% of the children with
IBD (7).
Endoscopic procedures in children should be performed
according to recent ESPGHAN/ESGE recommendations, including
in a pediatric-friendly setting (1). As stated in the ECCO guidelines
for histopathology in IBD, multiple biopsies from at least 4 sites
along the colon (cecum, transverse colon, sigmoid colon, rectum)
and the terminal ileum should be obtained and placed immediately
into separate vials, and should be accompanied by pertinent clinical
information (8). Multiple biopsies entail a minimum of 2 represen-
tative samples from each segment including macroscopically nor-
mal segments. The Porto criteria also advocate multiple biopsies
from the esophagus, stomach, and duodenum for all children with
IBD irrespective of upper symptoms (2).
Establishing a definite and accurate diagnosis in a patient
suspected of having IBD is mandatory. Therefore, complete evalu-
ation should be advocated. In patients transferred to a pediatric IBD
Unit without previously fulfilling Porto Criteria properly, a future
strategy to complete the diagnostic workup should be planned,
especially when a full IC has not been performed. If successful
treatment has been adequately initiated after the first endoscopy,
complete fulfillment of the Porto Criteria could be postponed.
Endoscopic findings can change over short periods of time. When
a colonoscopy has shown only non-specific findings, due to inter-
ruption or dissociation between endoscopy and histology, a new
endoscopy should be performed to better characterize the disease.
ENDOSCOPIC MONITORING
Recommendations:
(1) Endoscopic evaluation of the intestinal mucosa is recom-
mended in the following circumstances (EL3; RGC). (85%
agreement)
TABLE 2. Guideline recommendations
1. In non-emergency situations, the diagnostic evaluation for suspected IBD in children should include a combination of esophagogastroduodenoscopy (EGD)
and ileocolonoscopy (IC).
2. During IC and EGD, multiple biopsies (2) should be obtained from each segment even in the absence of macroscopic lesions.
3. Endoscopic evaluation of the intestinal mucosa is recommended in the following circumstances:
Before major treatment changes (escalating or de-escalating).
In symptomatic patients when it is not clear whether the symptoms are inflammation-related, such as when IBS is suspected to account for symptoms.
In CD to ensure mucosal healing during clinical remission.
In UC to ensure mucosal healing during clinical remission only if fecal calprotectin is elevated.
4. Following bowel resection, endoscopic evaluation should be performed 6-12 months later, aiming to identify postoperative recurrence.
5. Pouchoscopy is indicated to confirm suspected diagnosis of pouchitis, especially at the first episode.
6. Determining endoscopic activity with validated indices is recommended in clinical trials and it is suggested in clinical practice.
7. The recommended scores in adult and pediatric IBD are
The CD endoscopic index of severity (CDEIS) and/or the Simple Endoscopic Score for CD (SES-CD)
The Mayo endoscopic score or Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for UC.
The Rutgeerts’ score for assessing post-surgical CD recurrence in the neo-terminal ileum.
8. CE is complementary to MRE for evaluating SB inflammation. In suspected CD, either CE or MRE are recommended.
9. In established CD, MRE may precede or be preferred to CE, especially with risk of stenosis.
10. In the presence of high clinical suspicion for CD without stenosis, CE should be considered even after a negative magnetic resonance enterography, due to
the higher sensitivity for mucosal lesions.
11. Before performing CE, intestinal stricture or narrowing must be excluded, as capsule retention is the most relevant side effect of the procedure, although it
rarely causes any clinical sequelae.
12. The use of endoscopic disease activity scores is suggested to facilitate prospective SB CE follow-up and to evaluate response to medical therapy.
13. If intestinal stenosis is suspected or a biopsy is needed due to uncertain CE results, push or balloon-assisted enteroscopy is suggested.
14. Endoscopic balloon dilation is recommended in short (4 cm) and reachable strictures.
15. A surveillance program is suggested in pediatric UC after 10 years from the onset of disease. Surveillance may start as early as 8 years in older children (>16
years) if any of the following risk factors are present: extensive colitis; high burden of the colitis over time (a factor of severity and chronicity); and family
history of colorectal cancer in a first-degree relative at <50 years.
16. In IBD cases with concurrent primary sclerosing cholangitis (PSC), surveillance IC may be considered annually or at least bi-annually, starting from the
time of PSC diagnosis or shortly thereafter. However, in children <12 years of age, surveillance could be postponed depending on to the presence of
individual risk factors (disease duration, family history, severity of the disease over time and disease extent).
17. The endoscopic procedure for surveillance examination should be performed in a quiescent period of the disease to minimize false positive interpretation of
dysplasia.
CD ¼ Crohn disease; CE ¼ caspule endoscopy; EGD ¼ esophagogastroduodenoscopy; IBD ¼ inflammatory bowel disease; IC ¼ ileocolonoscopy; MRE ¼
magnetic resonance enterography; SB ¼ small bowel; UC ¼ ulcerative colits.
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- Before major treatment changes (escalating or de-escalat-
ing) (EL2; RGB).
- In symptomatic patients when it is not clear whether the
symptoms are inflammation-related, such as when IBS is
suspected to account for symptoms (EL3; RGC).
- In CD to ensure mucosal healing (MH) during clinical
remission (EL4; RGC).
- In UC to ensure MH during clinical remission only if fecal
calprotectin is elevated (EL3; RGC).
(2) Following bowel resection, endoscopic evaluation should be
performed 6 to 12 months later, aiming to identify post-
operative recurrence (adult EL3; RGC). (92% agreement)
(3) Pouchoscopy is indicated to confirm suspected diagnosis of
pouchitis, especially at the first episode (EL3; RGC). (87%
agreement)
(4) Determining endoscopic activity with validated indices is
recommended in clinical trials and it is suggested in clinical
practice [adult EL2, RGC]. (90% agreement)
(5) The recommended scores in adult and pediatric IBD are
- The CD endoscopic index of severity (CDEIS) [adult EL1]
and/or the Simple Endoscopic Score for CD (SES-CD)
[EL1].
- The Mayo endoscopic score or Ulcerative Colitis Endo-
scopic Index of Severity (UCEIS) for UC [adult EL3, RGC].
- The Rutgeerts’ score for assessing post-surgical CD
recurrence in the neo-terminal ileum [adult EL3]. (95%
agreement)
Practice points:
(1) It is important to report the extent and location of inflammation
and whether the inflammation is continuous, the presence of
erythema in each segment of the intestine; loss of vascular
pattern, bleeding (contact or spontaneous), presence of
erosions or ulceration (superficial or deep), and the presence
of strictures or fistulas.
(2) It is key to report the degree of change of endoscopic activity
since previous evaluation (ie, decreased, increased, equal).
(3) MH means a complete lack of inflammation (SES-CD¼ 0 and
Mayo/UCEIS¼ 0), while endoscopic remission is defined by a
SES-CD  2 and a Mayo or UCEIS  1. Endoscopic
Remission is practical and a more achievable target in clinical
practice; however, MH remains the ideal and potentially the
more relevant target.
(4) Endoscopic response is defined as a decrease in CDEIS >5 or
SES-CD  2 for CD, while a decrease in Mayo endoscopic
subscore  1 or in UCEIS  2 for UC. Using relative (rather
than absolute) changes, endoscopic response is a decrease
from baseline of at least 50%.
(5) The first MH evaluation after a major change of therapy can be
performed between 6 and 12 months in CD. High-risk CDwith
younger age at onset, extensive and/or severe disease, previous
drug unresponsiveness, and presence of stenosing or penetrat-
ing complications can be considered for evaluation of MH and
disease extent after 6 months.
(6) In CD, fecal calprotectin levels could influence timing of the
follow-up procedure.
(7) The MH evaluation in UC is indicated only in presence of
a discrepancy between PUCAI and fecal calprotectin
levels.
(8) The possible negative effects of repetitive general anesthe-
sia (GA) should be included in the decision making process
to balance the need of endoscopy with the risk of multiple
GA, especially in younger children with severe disease
course.
When to Evaluate
The usefulness of endoscopic reassessment should be indi-
vidualized according to the disease type, severity, risk of relapse
and risk of progression and in general, when a significant change in
medical management is contemplated. In pediatric IBD, the overall
rate of management change after endoscopy can be up to 42% of
cases (9). Unfortunately, the appropriateness of periodic endoscopic
reassessment after index IC has never been formally studied and its
value of it is much debated, especially in pediatric UC. Treatment
changes based on endoscopy are more frequent in children with CD
than UC (10). Clinical judgment and Pediatric Ulcerative Colitis
Activity Index (PUCAI) have been documented to be adequate for
the evaluation of disease activity in pediatric patients (11). A
PUCAI < 10 has been closely associated with MH and not inferior
to endoscopic evaluation in predicting clinically important out-
comes (12). Moreover, fecal biomarkers are being used more
recently as surrogate markers of disease activity, and fecal calpro-
tectin levels above 100mg/g correlate with mucosal inflammation
on endoscopy, especially in UC (13–16). Thus, it does not seem
justified to routinely recommend endoscopic assessment in pediat-
ric UC solely to assess disease activity, response to treatment or
at relapse.
Unfortunately, CD fecal biomarkers are unable to detect
mucosal relapse with the same accuracy as for UC, and endoscopy
is often required to identify presence of inflammation (17).
Endoscopic evaluation is recommended in any case before
major treatment changes (escalating and de-escalating treatment
strategies), to diagnose complications (eg, stenosis, dysplasia) and
to exclude other diagnoses, such as ischemia and rarely infection,
such as CMV (18).
In Clostridium difficile infection, evaluation by colonoscopy
may be misleading in active colitis, as typical pseudomembranes
are commonly absent (19,20). Moreover, full IC is not recom-
mended in severe colitis due to increased risk for serious complica-
tions such as perforation (21), even though it may be attempted
safely in expert hands (22).
In post-colectomy patients, initial clinical suspicion of pou-
chitis should be confirmed by endoscopic evaluation of the pouch
with mucosal biopsies, since irritable pouch syndrome is can
increase stool frequency and cramping despite normal pouch
endoscopy and histology (23).
The benefit of postoperative endoscopy in CD has not been
prospectively evaluated in children. A recent Australian study
demonstrated that adults who underwent IC 6 months after surgery
to decide on treatment adjustment, had considerably lower relapse
18 months after surgery (24). Extrapolation from these data in adults
suggests that a similar protocol may also be indicated in pediatric
patients to monitor for postoperative recurrence and treatment
aimed at relapse prevention (25).
How to Evaluate
Reporting of endoscopic disease activity should always
include accurate descriptors of any abnormalities in each segment
(26). Due to the variability between different operators, the scoring
of endoscopic disease activity is, however, becoming an important
clinical endpoint in clinical trials (27–29). The distribution and
severity of inflammation noted during endoscopy of children early
in the course of IBD may be patchy with a pattern that is less
commonly seen in adults with IBD. For this reason, scoring systems
used in adults may be difficult to extrapolate to children.
Despite their limitations, the use of an endoscopic scoring
system can, however, aid in reporting endoscopic findings and
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allow for easy comparisons between a patient’s current and previ-
ous endoscopy results. If it is feasible, we recommend the use of
endoscopic scores in clinical practice (30). Unfortunately, docu-
mentation of endoscopic disease activity remains generally subjec-
tive in children. For this reason, if the endoscopic scoring systems
are not used, it is important to document the following findings in
each segment of the bowel: the extent and location of inflammation,
if bowel involvement is continuous or involves skip areas, the
presence of erythema, loss of vascular pattern, bleeding (contact or
spontaneous), presence of erosions or ulceration (superficial or
deep), and the presence of strictures or fistulas. In addition, on
follow-up endoscopy, it is important to document the degree of
change of endoscopic activity since the previous evaluation.
Recently, several endoscopic scoring systems and indices
have been developed that are used as clinical trial outcome
measures. Few have been rigorously validated in adults, and
no reference standard exists for scoring endoscopic activity,
expect for the normal mucosa. Some indices form part of
composite scores that integrate clinical information (eg, the
Mayo endoscopic sub-score). Despite the relative simplicity of
scoring and category definitions, intra- and inter-observer differ-
ences among experts remain a significant weakness in current
scoring systems. Several scores include mucosal friability, which
is subject to intra- and inter-observer variation in definition and
interpretation. The most used and recommended scoring systems
and their current applicability, strengths and limitations in pedi-
atric IBD are listed in Table 3 (31–40). A wider application of
the scoring system and the development of newer scores will
help with comparisons of medication efficacies and also help
optimize a treat-to-target treatment algorithm in patient manage-
ment of pediatric IBD.
Mucosal Healing
MH evaluation is currently considered the ultimate treatment
target for IBD (41). Unfortunately, no well-validated and widely
accepted definition exists, creating considerable uncertainty regard-
ing an optimal approach to integrate MH into treatment outcomes
(42). Meanwhile, MH was demonstrated to be feasible in clinical
practice with cumulative MH probability of up to 70% in CD and
UC (43–50).
In UC, disease activity is limited to the colonic mucosa, thus
making it plausible for MH to represent the ultimate therapeutic
goal (51). Conversely, the definition of MH in CD is less easily
defined, given the transmural nature of the disease, the poor
correlation between symptoms (PCDAI) and mucosal inflamma-
tion, and the higher rate of upper GI tract involvement (often
beyond the reach of upper GI endoscopy) (52).
TABLE 3. Endoscopy: strengths and limitations of the most commonly used scores for inflammatory bowel disease
CD
Validation Strengths Limitations Year
CDEIS (Crohn’s Disease
Endoscopic Index of
Severity)
Yes Reproducible Complex score 1989
Sensitive to changes No cutoff validations
Gold standard for several years No data on long-term outcomes
SES-CD (Simple
Endoscopic Score for
Crohn’s Disease)
Yes Strongly correlation with CDEIS No cutoff validations 2004
Excellent Inter-observer agreement
Correlate with fecal calprotectin
Identify patients most likely in corticosteroid-free clinical
remission
Good agreement between sites and central readers
More responsive to change
The Rutgeerts Score (for
assessing after ileocecal
resection)
No Good risk prediction or recurrence Not commonly used in clinical
practice
1990
UC
Mayo No formal
validation
Widely used and accepted Only 4 scales 1987
No differentiation between deep
and superficial ulcers
No information on disease
extension
Presence of subjective item
(friability)
UCEIS (Ulcerative Colitis
Endoscopic Index of
Severity)
Yes High correlation with assessment of severity Need to establish thresholds 2012
Good intra and interobserver realiability Unknown clinical relevance of
different valuesScore 7 at admission in Acute severe UC correlates with
need for step-up treatment To be explored sensitivity to
changeCorrelates with fecal calprotectin
Strongly correlates with patient-reported outcomes
Knowledge of clinical details minimally affects UCEIS
UCCIS (Ulcerative Colitis
Colonoscopic Index of
Severity)
No
Greater interobserver variability in right colon Need to establish cutoff values 2013
Good correlation with clinical and laboratory parameters No data on outcomes
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Recently, the International Organization for the Study of
Inflammatory Bowel Diseases (IOIBD) (41) published a position
paper defining the treatment targets and MH definition. For adult
patients, MH was described as the absence of all visible ulcers (41).
Although this definition is simple to apply in clinical practice, it is
relatively insensitive to change and does not allow for a quantifi-
cation of overall improvement or improvement beyond ulcer heal-
ing (53). For this reason, scoring systems are of critical importance
in defining MH in clinical practice (27–29). Complete MH is
defined as a SES-CD or CDEIS and a Mayo or UCEIS of 0, while
a SES-CD or CDEIS 2 and a Mayo or UCEIS 1 have been
considered endoscopic remission in CD and UC, respectively
(26,34,42). Nevertheless, a Rutgeerts score value of <i2 is consid-
ered endoscopic remission after surgery in CD (54). Endoscopic
remission is practical and a more achievable target in clinical
practice; however, MH remains the ideal and potentially the more
relevant target. Moreover, in cases where MH or endoscopic
remission cannot be achieved, it is important to evaluate at mini-
mum the treatment efficacy by defining the endoscopic response
at least.
The IOIBD defines endoscopic response as a decrease in
CDEIS >5 or SES-CD 2 for CD, while a decrease in Mayo
endoscopic subscore 1 or in UCEIS 2 for UC (55). Using
relative (rather than absolute) changes, endoscopic response is a
decrease of at least 50% from baseline. Indeed, a recent post hoc
analysis of the SONIC trial showed that endoscopic response could
be defined as a decrease of at least 50% from baseline (55).
Few studies have attempted to determine optimal timing for
evaluation of MH in CD after a major change of treatment.
Recently, Bouguen et al showed that shorter times between endo-
scopic procedures with consequent adjustments in medical therapy
if ulcers were identified were associated with a higher rate of MH
(45).
Emerging data also indicate that early MH may be more
important than baseline disease severity or timing of drugs for
predicting sustained long-term remission (47–48). Projecting these
data to endoscopy, achieving MH early in disease is an important
target that may ultimately alter the natural history of the disease.
Indeed, early MH rather than early treatment drives improved
outcome (56).
Moreover, the time frame for MH to occur while on treatment
ranged from 10 to 26 weeks, with higher rates of MH seen at later
time points from various controlled trials (44,57,58). According to
these data, a 26-week (6 month) assessment may be associated with
an improved MH rate. The first MH evaluation after a major change
of therapy can be performed between 6 and 12 months in CD. Risk
stratification of the disease could help define the exact timing.
High-risk CD can be defined including younger age at onset,
extensive and/or severe disease, previous drug unresponsiveness,
and presence of stenosing or penetrating complications (59,60).
After appropriate treatment patients at high risk for progression
should be reassessed at 6 months for MH (59).
It is important to note that for the purpose of MH, a risk to
increase the frequency of endoscopic procedures may exist, making it
likely that pediatric IBD patients will undergo multiple episodes of
GA (61). Preliminary reports, mainly on animals, have suggested
potential long-term negative side effects of GA applied in children
(62–67), thus giving reason to pause before complying with this
strategy (68–69). On the other hand, a considerable proportion of
patients in clinical remission may not have MH and go undetected
without endoscopy. A recent pediatric study demonstrates that
despite being in clinical remission, up to 30% of patients with
IBD revealed active disease on first endoscopy after 1 year. Leaving
inflammation untreated in carries a significant risk in long-term
outcomes (56). Identifying active patients and altering treatment
may halt disease progression. Similar findings have been shown in
a review of the SONIC data and data from clinical practice (45,46,55).
SMALL BOWEL ENDOSCOPY
Recommendations:
1. Capsule endoscopy (CE) is complementary to magnetic
resonance enterography (MRE) for evaluating SB inflammation
[EL3, RGC]. In suspected CD, either CE or MRE are
recommended. [EL3, RGC]. (87% agreement)
2. In established CD, MRE may precede or be preferred to CE,
especially with risk of stenosis. [EL3, RGC]. (97% agreement)
3. In the presence of high clinical suspicion for CD without
stenosis, CE should be considered even after a negative MRE,
due to the higher sensitivity for mucosal lesions [EL3, RGC].
(92% agreement)
4. Before performing CE, intestinal stricture or narrowing must be
excluded, as capsule retention is the most relevant side effect of
the procedure, although it rarely causes any clinical sequelae.
[EL3, RGC]. (95% agreement)
5. The use of endoscopic disease activity scores is suggested to
facilitate prospective SB CE follow-up and to evaluate response
to medical therapy [EL4, RGC]. (82% agreement)
6. If intestinal stenosis is suspected or a biopsy is needed due to
uncertain CE results, push or balloon-assisted enteroscopy is
suggested [adult EL3, pediatric EL4/RGC]. (85% agreement)
Practice points:
1. There is no accepted protocol for preparation before CE;
however, prior bowel cleansing may improve SB visualization.
Protocols range from overnight fasting to standard IC bowel
preparations. The protocol including low-dose PEG-solution
(25mL/kg up to 1L the day before) and oral simethicone (just
before capsule ingestion) resulted in the best visualization score
and is currently suggested.
2. CE is approved for the use in children of 2 years and older that
are able to swallow the capsule. Positioning of the capsule by
endoscopy under GA is usually feasible in children with a body
weight of at least 8 kg.
3. In suspected CD, the choice to perform CE, MRE or both,
depends on local availability and expertise.
4. Strictures can be assessed before CE either by MRE, patency
capsule or by a combination of these methods. When an
intestinal narrowing is suspected by MRE, patency capsule
should be performed before CE examination.
5. CE findings assist in directing the most effective route of
enteroscopy intubation (oral vs anal) according to lesion
location.
6. The use of Lewis score (LS) is suggested, since it is the most
widespread and known score, which can be easily calculated by
using CE software. A score <135 is designated normal or
clinically insignificant mucosal inflammatory change, a score
between 135 and 790 is mild, and a score >790 is moderate
to severe.
7. The choice between CE or enteroscopy could also be dictated
by the local availability of procedures and expertise. Nonethe-
less, due to its lesser invasiveness, CE is usually preferable in
the absence of strictures.
Capsule Endoscopy
CE is a feasible and useful endoscopic procedure for diag-
nosing intestinal diseases in pediatric patients (70). IC together
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with EGD, both with biopsies, still remain the most important and
defining endoscopic approach in the diagnosis and management of
IBD. To properly define the diagnosis (CD vs UC vs IBDU) and
disease phenotype, SB imaging is needed as described in the
revised Porto criteria (3). In most patients, MRE would be the
method of choice for this part of the diagnostic evaluation. CE,
however, has higher sensitivity for mucosal lesions (especially
in the proximal SB) and may add conclusive information in
defining diagnosis or disease phenotype in case of a negative
MRE (71). Conversely, it can rule out IBD due to a high negative
predictive value for active SB CD. CE can detect inflammatory
changes (aphthous ulcers) of the intestinal mucosa and MH.
Identification of the region of the SB cannot always be reliably
determined by tracking information provided by external sensors.
Furthermore, the SB CE transit time percentage may be more
accurate. Pediatric studies (71–73) have shown that the findings
of CE in CD patients result in therapeutic consequences in up to
75% to 92%. Aloi et al, showed that sensitivity and specificity of
CE, MRE and contrast enhanced SB ultrasound (SICUS) are
similar (74).
Some recent adult studies have shown that CE may be
superior to MRE, particularly for the detection of early disease
and proximal SB lesions (75–77). For this reason, ESGE
recommends CE as the initial modality for investigating the
SB in suspected CD without obstructive symptoms or known
stenosis. Conversely, in established CD, the ESGE recommends
dedicated cross-sectional imaging as first step, leaving CE as a
subsequent investigation, if deemed to influence patient man-
agement (78).
According to pediatric and adult evidence-based studies, CE
can be considered complementary to MRE as it is much more
sensitive for evaluating mucosal lesions, while MRE is more
specific for extramural and mural findings (79). Indeed, CE can
detect residual inflammation even in the presence of normal serum
and fecal inflammatory markers (80). It can also confirm SB MH
after commencing a new treatment (81).
The capsule is usually expelled within 2 weeks after deploy-
ment into the GI tract. Longer intervals are defined as ‘‘capsule
retention.’’ This seems to be more frequent in pediatric IBD-
patients than in adults. It is reported in a mean of 2.5% of pediatric
patients, up to 43% in pediatric IBD-patients with malnutrition, and
in 37.5% of CD patients with known SB disease (82,83). Possible
interventions are endoscopic removal if reachable (eg, stomach or
ileal pouch), high volume bowel cleansing, anti-inflammatory
treatment with steroids or, in rare cases of bowel obstruction,
surgical removal. Mid-SB retention if clinically important can be
resolved often by double-balloon enteroscopy retrieval. Long-term
retention is described, but rarely is it clinically important. Usually it
is more indicative of pathology that requires definitive treatment,
particularly if the patient is symptomatic. An individualized
approach is advisable depending on the clinical situation of
the patient.
A patency capsule is available to avoid capsule retention.
The purpose of this tool is to prevent capsule retention by pre-using
a ‘‘capsule-dummy’’ that dissolves via its 2 open ends and thus be
‘‘crushed’’ and expelled by intestinal motility in the case of delayed
passage. Its presence in the intestine can either be detected by a
special radiofrequency device or x-ray.
Strictures can be assessed before CE either by MRE, patency
capsule or by a combination of these methods. Although findings of
small-bowel stenosis at MRE may preclude subsequent CE in 27%
to 40% of patients with known CD (84), not all strictures actually
result in significant mechanical obstruction and the use of the
patency capsule may help to identify patients who are at increased
risk of capsule retention (85,86).
A recent adult study shows that MRE has a high negative
predictive value and sensitivity for patency capsule retention. When
capsule retention is suggested by MRE, patency capsule should be
performed before the CE examination. The maximal stricture length
(>10 cm) and the number of pre-stenotic dilations were found to be
the most predictive imaging features for patency capsule retention
(87).
CE is approved for children 2 years and older. Nevertheless,
case series report successful use in children with a minimal age of
8 months or a minimal weight of 7.9 kg (88). Swallowing the
capsule can be achieved by most children (89). In the majority
of younger children, an application device is needed to front load
the capsule to the endoscope releasing it directly into the duodenum.
Mean SB transit times are reported in the range between 175 mins to
401 mins (82).
No generally accepted pre-CE protocol exists at this time. CE
manufacturers did not recommend pre-procedure purgative use for
CE. The recommended requirements were only a low fiber diet with
clear liquids and a 12-hour fast on the day before. Over the last few
years, different randomized controlled studies have addressed the
question of whether purgatives improve mucosal visibility, diag-
nostic yield and completion rate (90–96). To date, 4 meta-analyses
have concluded that the ingestion of 2 liters of PEG solution prior to
capsule leads to improved visibility of the SB mucosa. However, the
evidence relating to completion rates and diagnostic yield is still
inconclusive and the optimal timing for purgative use is yet to be
established (97–101). The only pediatric RCT, (102) recommends
bowel-cleansing with 25 mL/kg PEG-solution (up to 1 L) the even-
ing before the examination with an overnight fast and subsequent
20 mL oral simethicone just before ingestion/application, as this
resulted in the best visualization score. The same protocol has been
recently endorsed by both NASPGHAN and ESGE (103). Other
standard IC cleansing regimes are probably just as effective,
although simethicone is recommended to decrease bubble artifact.
Capsule Endoscopy Scoring System
Recent adult guidelines recommend the use of validated
endoscopic scoring indices for the assessment of small-bowel
inflammatory activity in patients with CD undergoing CE (78).
These scores aim to standardize the description of lesions in CE
reports, hence increasing inter-observer agreement and providing a
reproducible method for assessment of endoscopic activity that
could be used to stratify disease severity, guide the decision in the
appropriate medical management to monitor the response to therapy
and evaluate MH in SB (78,104,105). Nevertheless, these scoring
systems results are not diagnostic due to the lack of specificity of the
evaluated parameters and should instead be integrated in the
appropriate clinical context (41,78). LS and CE Crohn’s Disease
Activity Index (CECDAI) are the 2 validated scores currently
available to assess inflammatory changes in small-bowel mucosa
(104,106–109). Few studies have compared both scores (97), and
the majority of literature references the LS. For this reason, the LS
may be used for diagnosis in clinical practice, staging, follow-up
and therapeutic assessment of pediatric patients with SB CD. A
score<135 is designated normal or clinically insignificant mucosal
inflammatory change, a score between 135 and 790 is mild and a
score >790 is moderate to severe (104,107,109,110).
Enteroscopy
Enteroscopy (ES) is mainly used in adult patients, although
some pediatric studies report diagnostic yield and safety in selected
patients with suspected CD (111–112). Large prospective studies
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are necessary to identify the role of ES in the diagnostic algorithm
of IBD in children. Certainly CE may be complemented by tissue
acquisition by ES, although for simple diagnostic purposes CE is the
first line investigation. ES should not be used as an initial SB
diagnostic test for suspected IBD unless significant small intestinal
strictures, which are present that would be a contraindication to CE
use. No validated ES scores have been developed for diagnosis or
assessment of severity of SB CD. Firm evidence of the role of ES in
IBDU is lacking (113).
ES is indicated to obtain mid small intestinal biopsies, to
perform therapeutic procedures such as balloon dilation of stenosis,
or when a suspected obstruction or narrowing prevents application
of CE. Pediatric endoscopists are gaining experience with this
technique. However, in some centers ES is still performed by adult
practitioners (114), who should be fully educated in specific aspects
of pediatric IBD. In general, the decision whether to perform CE or
ES in pediatric IBD may depend on local availability and expertise
(113). Nonetheless, due to its lesser invasiveness, CE is usually
preferable in the absence of strictures. General considerations
specific to ES procedures in children (eg, age limitations, GA,
instrument(s) employed) should be considered when deciding
whether or not to perform this procedure. ES is safe in both adults
and children; however, it is associated with higher risk compared to
CE (115–119). CE findings may help direct the most effective route
of ES intubation (oral vs anal), although both approaches may be
required (120–122).
THERAPEUTIC ENDOSCOPY
Recommendations:
(1) Endoscopic balloon dilation is suggested in short (4 cm) and
reachable strictures. [adult EL2, pediatric EL3 RGC]. (82%
agreement)
Practice points:
(2) In case of longer (>4 cm), primary, and/or multiple strictures,
it is recommended to avoid endoscopic balloon dilations
(EBDs) due to the higher risk of complications and lower
success rate
(3) Before EBD, it is recommended to characterize the number,
nature (inflammatory vs fibrotic) and length of the strictures by
using MRE or small intestine contrast ultrasonography.
(4) It is suggested to refer patients to surgery (resection/
strictureplasty) or EBD taking into account the procedural
expertise of the endoscopist, patient preference, the probability
of success, and the specific nature of the stricture.
(5) In presence of fistulizing disease and abscesses at or adjacent
to the site of the procedure, EBD is not recommended due to
the increased risk of perforation.
(6) Using intra-lesional injections of corticosteroids or infliximab
during endoscopic balloon dilatation or intra-luminal stents is
not recommended due to insufficient evidence.
Approximately 50% of patients with CD will require
surgical intervention within 10 years from initial diagnosis,
primarily due to stricturing and penetrating complications
(123–125). Stricturing disease has been demonstrated to be an
independent risk for the need of surgery with a cumulative risk of
64% after 10 years (126). In CD, strictures are typically found in
the TI, colon and in surgical anastomoses (127). Even though
intestinal strictures are not as common in pediatric CD as in adult
CD, these are still a major cause of morbidity and one of the
leading causes for surgery with a cumulative incidence of 20%
10 years after diagnosis (128). In general, the term ‘‘Therapeutic
Endoscopy’’ in IBD refers to endoscopic dilatation or stenting of
strictures in CD. It is widely accepted that the treatment of choice
for permanent non-inflammatory fibro-stenotic strictures in CD,
surgery is most commonly a limited ileo-colonic resection (129)
with surgical strictureplasty as an alternative approach to preserve
bowel length (130). Few pediatric reports are available regarding
post-operative recurrence rate (131). Adult-based literature indi-
cates a high rate of recurrence resulting in reoperation (123,132).
Over the last 20 years, EBD has emerged as a safe and effective
alternative to surgery in adult CD, particularly in cases of ileo-
cecal and anastamotic strictures (133–158). Immediate technical
success of EBD defined as the ability to pass through the stricture
with the scope, varies between 86% and 94% in different series
(133,157). The cumulative long-term success defined as surgery-
free rates following EBD ranges between 83% and 87%, 58% and
72%, and 64% and 58% at 1, 3, and 5 years, respectively (133–
158). In the only published pediatric study (159) describing 29
patients undergoing EBD, a 1-year surgical rate was reported as
14%, in concordance with adult data. Stricture recurrence rates of
strictures requiring re-dilatation following EBD are reported to be
20% to 30%, 50% to 60%, and up to 70% at 1, 3, and 5 years,
respectively (136,138,142,154,157). With the lack of controlled
trials comparing EBD to surgical techniques, insufficient evi-
dence exists to conclude whether these rates are comparable to
post-surgical recurrence that is reported as 45% at 5 years (153).
Median time for surgery and re-dilation following EBD in
patients with recurrent strictures has been reported as 12.8 to
14.5 and 14 months, respectively (156,157).
Surgery-free outcome is reported to be the highest when
stricture length is <4 cm and when EBD is performed for anasto-
motic strictures (133,145,146,150). It is not clear whether outcome
is affected by factors such as concurrent medical therapy, smoking
status and disease activity (151,156,160,161), even though smoking
was suggested as a risk factor for recurrence (143,160). Neverthe-
less, longer CD duration and higher C-reactive protein levels
are reported to be associated with an increased need for subsequent
surgery following EBD (159). It is also not clear whether
recurrence rates differ between primary and anastomotic strictures
(155,161). Two recent studies show a significantly lower long-term
success rate in patients with a primary stricture of the ileocecal
valve or the terminal ileum (145,157). The presence of a stricture on
the ileocecal level was reported as a negative predictive value in the
long term with a higher rate of surgery (154).
The reported complication rate, including bowel perforation
and significant bleeding (133), is approximately 2% for EBD
compared with a 5% complication rate in strictureplasty (153).
The presence of fistulizing disease and abscesses at or adjacent to
the site of procedure are considered contraindications to EBD since
both are believed to increase the risk of perforation (132).
Procedural aspects including balloon caliber, duration and
number of dilatations required are variable (132), although most
studies used a caliber of up to 18 mm with a maximal caliber of
25 mm. A recent study shows excellent results with balloons used
for dilatation up to 18 mm, no more than 90 seconds of insufflation
time, and no more than 6 dilatations per session (156). It seems that
the risk of more complications is increased when using larger
balloons (>20 mm) (141).
Intra-lesional injection of infliximab (162,163) or steroids
(159,164–167) to improve the long-term efficacy of EBD has been
reported and reveal variable results. In the only pediatric study
using EBD published to-date (159), 29 patients were randomized to
receive intrastricture injection of corticosteroid or placebo after
EBD. The 2 groups statistically differed in the time free of re-
dilatations and for time free of surgery after EBD, which were
worse in the placebo group (159). One report suggests that
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postdilation topical application of the anti-fibrotic Mitomycin C
may be of value; however, this needs further verification (168).
Only a few uncontrolled studies report on intraluminal stents
for adult CD with no control groups (169–172). The current
evidence is not strong enough to support recommendations for
using stents for pediatric CD strictures.
In UC, following ileal-pouch anal anastomosis, mechanical,
inflammatory and function complications can occur. One of the
mechanical complications is the ileal-pouch stricture, which has
been reported in 10% to 40% of cases (173). Two common locations
prone to develop strictures are (1) the pouch-anal anastomosis
(pouch outlet) and pouch inlet at the junction of the neo-terminal
ileum, and (2) within the pouch. Management of the pouch stric-
tures, especially inlet stricture, can be challenging. Limited data
regarding endoscopic management of pouch strictures are available,
although EBD is evolving as a comparably effective alternative to
surgical strictureplasty in adults (174). Preliminary evidence sug-
gests similar complication rates but with higher recurrence rate
following EBD (174). Currently, no scientific evidence supports the
use of EBD in ileal-pouch strictures in children.
CANCER SURVEILLANCE
Recommendations:
(1) A surveillance program is suggested in pediatric UC after
10 years from the onset of disease. Surveillance may start as
early as 8 years in older children (>16 years) if any of the
following risk factors are present: extensive colitis; high
burden of the colitis over time (a factor of severity and
chronicity); and family history of colorectal cancer in a first-
degree relative at <50 years [EL5, adults EL2; RGC]. (85%
agreement)
(2) In IBD cases with concurrent primary sclerosing cholangitis
(PSC), surveillance IC may be considered annually or at least
bi-annually, starting from the time of PSC diagnosis or shortly
thereafter. In children <12 years of age, surveillance could,
however, be postponed depending on to the presence of
individual risk factors (disease duration, family history,
severity of the disease over time and disease extent) [EL4;
RGC]. (90% agreement)
(3) The endoscopic procedure for surveillance examination
should be performed in a quiescent period of the disease to
minimize false positive interpretation of dysplasia [EL4;
RGC]. (95% agreement)
Practice points:
The screening program should be performed by an experi-
enced pediatric or adult gastrointestinal endoscopist.
(1) Surveillance intervals should be individualized according to a
risk stratification (extensive colitis; high burden of the colitis
over time; and family history of colorectal cancer): annually in
those at high risk (>2 factors); every 3 years in those with an
intermediate risk (>1 factor); and every 5 years in those
without any risk factors.
(2) The combination of high definition (HD) IC and/or
chromoendoscopy with indigo carmine or methylene blue
spraying is recommended for performing surveillance when
possible, otherwise, Narrow Band Imaging (NBI) can also be
used. Chromoendoscopy can help target discrete macroscopic
lesions.
(3) Confocal laser endomicroscopy (CLE) may have a role in
characterizing lesions identified during surveillance.
(4) When HD endoscopy or chromoendoscopy is not available, a
high number of random biopsies along the entire colon (2–4
biopsies of 4 segments each 10 cm) should be obtained. Extra
biopsies can be obtained from strictured, raised, or color-
changed areas in the colorectal mucosa.
Recommendations for endoscopic surveillance for colorectal
cancer (CRC) to date include variables, such as starting time of the
program, interval of colonoscopies, best endoscopic technique and
management of the mucosal abnormalities detected can vary.
It is widely agreed that surveillance IC should be recom-
mended 8 years after diagnosis, thus pediatric gastroenterologists
may still be involved since many patients in the pediatric age range
experience an early disease onset (26).
Individuals who have had a long-standing history of colonic
IBD have an increased risk of developing colorectal cancer (CRC)
compared with the general population. Moreover, a recent pediatric
report demonstrated that this risk is higher even for other type of
cancers (175).
A longer duration of colitis seems to increase the risk of IBD-
associated CRC; previous data show a cumulative rate of 1.6%,
8.3%, and 18.4% at 10, 20, 30 years, respectively (176). Recent
reports indicate a decline in this rate to 2.5%, 7.6%, and 10.8% at
20, 30 and 40 years, respectively (177). Lakatos et al reported a
cumulative risk of 0.6%, 5.4%, and 7.5% at 10, 20, and 30 years in a
Hungarian IBD population (178). Interestingly, the incidence rate of
CRC in UC seems to be declining, that is, 2-to-3 times higher than
that of the general population (179). It is tempting to suggest that
optimizing inflammation-suppressing therapy and endoscopic sur-
veillance could explain this reduced incidence.
Other independent risk factors for CRC include the extent
and severity of mucosal inflammation. Ekbom et al reported a
standardized incidence ratio (SIR) for CRC of 1.7 for proctitis, 2.8
for left-sided disease and 14.8 for pancolitis (180), whereas Soder-
lund et al documented SIR of 1.7 for proctitis and 5.6 for pancolitis
(181). In a case-control study, Rutter et al found a significant
correlation between disease severity and cancer risk (OR of 2.5
for colonoscopic and OR of 5.1 for histological inflammation)
(182). Postinflammatory polyps are a marker of inflammation
and are therefore also associated with an increased CRC risk.
Family history of CRC will also increase risk (by 2–3-fold)
(183). A meta-analysis suggests that PSC is a further independent
risk factor for IBD-associated CRC with an OR of 4.04 when
compared with UC without PSC (184).
Patients with PSC and UC have a greater risk of malignan-
cies, such as colorectal cancer and cholangiocarcinoma (8%–30%
of UC patients with long-standing PSC) (185,186). A recent
European study on cancer and mortality in children has demon-
strated many cases associated with PSC (187). PSC is associated
with more extensive disease, thus predisposing to greater cancer
risk (188) even though the disease course of the colitis is milder
when associated with PSC. The higher colectomy rate in these
patients is secondary to dysplasia and CRC. Older age at PSC
diagnosis increases the risk of colonic neoplasia (188).
Childhood age at diagnosis of colitis may be an independent
risk factor for IBD-associated CRC. In a meta-analysis, Eaden et al
reported on 5 studies with pediatric follow-up data (177). The
average age of onset of UC was 10 years and mean duration of
follow-up was 12 years. The overall incidence of CRC for any child
was 6/1000 person years duration (pyd). The cumulative probability
of any child developing cancer was 5.5%, 10.8%, and 15.7% at 10,
20, and 30 years, respectively. Ekbom et al also found young age to
be associated with an increased risk of developing CRC (180).
When adjusted for disease extent, they calculated an SIR of 0.51
with each increase in age group. This age association has, however,
not been consistently found. For example, Rutter et al found risk to
increase with age of onset (177,178,189,190).
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Although the pediatric phenotype is often characterized by
extensive and severe disease and the younger age is associated with
increased risk of CRC, only a few childhood-onset CRCs associated
with IBD have been reported (181–183,191). de Ridder et al
recently conducted a multinational-based survey of cancer and
mortality in pediatric IBD on behalf of the ESPGHAN Porto
Working Group. Among 18 cases with a diagnosis of cancer under
the age of 19, colonic adenocarcinoma was reported only in 1, a boy
diagnosed with UC at 3 years who subsequently developed cancer at
16 years (187).
The paucity of pediatric CRCs is consistent with the findings
of a recent systematic review of the natural history of pediatric onset
IBD (191). Only 1 CRC was reported in the pediatric age group, a
15-year old child, 3 years after a diagnosis of UC (192). In the other
cases, cancer developed in adulthood (193–197). A recent popula-
tion-based study of the EPIMAD registry, including 698 children
with IBD (529 CD) followed for a median of 11.5 years, docu-
mented 9 cancer cases (2 CRCs) (198). None of the colon cancers,
however, presented in childhood. For all these factors, it seems
reasonable to consider a surveillance program in children after
10 years from diagnosis. In cases that include a history of extensive
and untreatable colitis over time (a factor of severity and chronicity)
and with a family history of colorectal cancer in a first-degree
relative at <50 years, the surveillance program may be considered
after 8 years from diagnosis in older children (>16 years) with the
same adult protocol (26).
The endoscopy program of surveillance has significantly
decreased the incidence of CRC in IBD mainly with the advent
of novel techniques (199,200).
Macroscopic abnormalities of colonic mucosa of IBD
patients are not readily detected in cases of dysplasia, but rather
is found primarily in flat dysplasia. Careful examination may
sometimes reveal slight modifications of the submucosal vessels,
an achromic plaque or an erythematous area with a granular
appearance, nodules or a pseudovillous appearance (201,202).
Dysplasia-associated lesions or masses (DALM) are raised
lesions that can be seen as irregular mucosal surface, nodules, or
sessile or more rarely, pedunculated polyps (203,204). The latter are
difficult to distinguish from either inflammatory pseudopolyps or
sporadic colonic adenomas.
Globally, the sensitivity of dysplasia detection is reported to
be between 20% and 72% (205,206). As the most frequent dys-
plastic lesions during IBD are almost invisible, adult guidelines
recommend performing a high number of random biopsies along
the entire colon (207). Extra biopsies can be obtained from
strictured, raised, or color-changed areas in the colorectal mucosa
(177,208–212). However, this method can be time consuming
and laborious.
Different chromoendoscopy techniques have been devel-
oped, using indigo carmine or methylene blue coloration of the
colon by endoscopic spraying to improve sensitivity (211,213,214).
Indigo carmine is a superficial contrast that reveals slight mod-
ifications of the mucosa surface, while methylene blue is massively
absorbed by normal mucosal, which does not color inflammatory
and dysplastic areas. Using these mucosal dyes, analysis of the pit
pattern is easier, allowing differentiation of a dysplasic lesion from
normal mucosa with a sensitivity and specificity of approximately
90% (214,215).
Chromoendoscopic analysis can also be performed using
new endoscopic techniques, which aim at visualizing detailed
surface architecture of the mucosa, vascular patterns, and even
the cellular and subcellular structures in real time. Precise observa-
tion and targeted biopsy are possible with the progress of novel
technologies, with HD endoscopy evolving into the standard tool
that is widely used in clinical practice and is often combined with
chromoendoscopy or NBI. More sophisticated imaging techniques
such as CLE are widely used, but experience is limited to a few
documented reports and centers. Only 1 study reports the applica-
tion of CLE in children (216); most data come from adult literature
(217,218).
Although NBI and focused chromoendoscopy increase the
detection rate of high-grade dysplasia among sporadic adenomas
(219), these optical chromoendoscopy techniques are less accurate
than dye-based chromoendoscopy to diagnose IBD-associated dys-
plasia (220).
At the histological level, dysplasia is defined as an epithelial
neoplasia with no invasion of the lamina propria (221), defined by
histopathology as indefinite, low and high dysplasia (222).
No clear evidence exists to suggest that endoscopic surveil-
lance of dysplasia decreases mortality due to CRC in IBD patients,
even if carcinomas are detected at an earlier stage (180,222).
The frequency of endoscopic surveillance is not clearly
defined. Recently it has been suggested that two-thirds of IBD-
associated CRC cases can arise from an insufficient surveillance
strategy, including poor bowel preparation and inadequacy of both
surveillance interval and dysplasia management (223). Considering
the lack of sufficient experience in this field, pediatricians should
plan and perform the screening program together with an endoscopy
surveillance expert.
CONCLUSIONS AND FUTURE PERSPECTIVES
Endoscopic techniques will be increasingly utilized in the
management of pediatric IBD in the near future, particularly with
the advent of ‘‘tight control’’ of the disease transforming our
concept of therapeutic targets (224). For this reason, the use of
new and non-invasive technologies is increasing over the time.
Colon capsule endoscopy (CCE) is a novel technique to examine the
colon (225). The application of colon capsule in the assessment of
pediatric IBD is yet to be determined. An initial report is promising
with a high specificity (100%) and sensitivity (96%) compared with
IC (226). However, this contrasts with lower diagnostic yields in
adult IBD studies (227,228). Bowel cleansing and a small risk of
retention are the possible drawbacks (227). Despite these limita-
tions, CCE offers another option to examine the pediatric large
bowel where IC cannot be completed, except in the presence
of strictures.
Although CCE is primarily aimed at the assessment of the
colon, images of the entire GI tract can be obtained. This has
prompted interest in establishing its potential for pan-intestinal
endoscopy (229–230). Recently, CCE has proven to be effective
in evaluating both SB and colon in pediatric CD in compared with
other imaging modalities and standard IC. CCE allows assessment
of the entire GI tract with a high diagnostic accuracy (sensitivity of
89% and specificity of 92%) (231). Hence, CCE may be considered
as a noninvasive means to evaluate both SB and colon as ‘‘one-
step’’ device. The combined CCE may also alter the monitoring of
pediatric IBD, with the potential benefit to reduce costs and the need
for anesthesia.
Based on these emerging data on the usefulness of panenteric
endoscopy for monitoring IBD, a SB and colon (SBC) capsule was
designed to image the SB and colon, replacing multiple diagnostic
procedures in CD patient management without sedation. The SBC
capsule is similar to the CCE in all its hardware components,
although it differs in its operational mode and is specifically
designed to provide complete coverage of the SB in addition to
the colon. Preliminary data in 66 adult CD suggest that the
diagnostic yield for SBC may be higher compared with standard
IC (83.3% vs 69.7%, respectively). Further prospective studies are,
however, needed to corroborate these data, especially in pediatrics.
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The advent of these non-invasive technologies may change tech-
niques to monitor IBD activity. Indeed, a recent pediatric study
confirmed the ability of CCE in guiding therapy in a treat-to-target
strategy of pediatric IBD, demonstrating a significant increase of
MH and deep remission rate (232).
The challenge to use more minimally invasive endodiag-
nostic tools in children will be maintained going forward (233).
Use of these tools will be weighed against their lack of tissue
histology (59).
Endoscopy in pediatric IBD provides a more definitive
diagnosis and disease extent evaluation, assesses therapeutic effi-
cacy and leads to a targeted therapy, which lessens complications
and progression. Future studies will confirm these goals and help
establish the best time-points and modalities for the application of
endoscopy in a treat-to-target strategy of IBD in children, adoles-
cents, and young adults.
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